Jan 06, 2022 / 07:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon. Thank you for joining us for the Goldman Sachs CEO Unscripted Conference. We're really pleased to have Stephane Bancel, CEO of Moderna. To start off, Stephane, thank you for joining us, and happy new year. To start off here, Moderna has announced in vitro data suggesting that the current COVID-19 vaccine formulation has good potential for cross protection against Omicron. Could you provide an overview of what we know thus far about Omicron and Spikevax's ability to address this variant?
Questions and Answers:
Stephane Bancel - Moderna, Inc. - CEO & DirectorSure. So good afternoon. Happy new year, Salveen, and thank you so much for having us today. So as we've shared publicly, very similar to other vaccines, given the big genetic drift between the Wuhan strain and the Omicron strain, as anticipated, when we just saw the sequence on Thanksgiving weekend. We're seeing a very material drop of neutralizing antibody post the second dose. The great news is that with